{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:37:17Z","timestamp":1784309837633,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jad.2022.01.004","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T07:44:37Z","timestamp":1641541477000},"page":"99-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Olanzapine and samidorphan combination treatment: A systematic review"],"prefix":"10.1016","volume":"301","author":[{"given":"Muhammad Youshay","family":"Jawad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazen","family":"Alnefeesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanna M.W.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Ceban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.J.","family":"Chen-Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saja","family":"Jaberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily S.","family":"Gillissie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D. Di","family":"Vincenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2022.01.004_bib0001","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jad.2022.01.004_bib0002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.schres.2017.01.002","article-title":"Efficacy, acceptability and tolerability of 8 atypical antipsychotics in Chinese patients with acute schizophrenia: a network meta-analysis","volume":"185","author":"Bai","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2022.01.004_bib0003","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12786","article-title":"Olanzapine plus samidorphan (ALKS 3831) in schizophrenia and comorbid alcohol use disorder: a phase 2, randomized clinical trial","volume":"81","author":"Brunette","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2022.01.004_bib0004","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"Suppl 7","key":"10.1016\/j.jad.2022.01.004_bib0005","first-page":"4","article-title":"Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia","volume":"65","author":"Casey","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2022.01.004_bib0006","first-page":"357","article-title":"Global economic burden of schizophrenia: a systematic review","volume":"12","author":"Chong","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2022.01.004_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004367.pub2","article-title":"Olanzapine in long-term treatment for bipolar disorder","author":"Cipriani","year":"2009","journal-title":"Cochrane Database Syst. Rev. CD004367."},{"key":"10.1016\/j.jad.2022.01.004_bib0008","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2165\/11589060-000000000-00000","article-title":"Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder","volume":"31","author":"Citrome","year":"2011","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.jad.2022.01.004_bib0009","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1176\/appi.ajp.2020.19121279","article-title":"Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study","volume":"177","author":"Correll","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2022.01.004_bib0010","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1177\/0269881119856850","article-title":"Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates","volume":"33","author":"Cunningham","year":"2019","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.jad.2022.01.004_bib0011","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1096\/fj.09-143610","article-title":"\u03ba-opioid receptors control the metabolic response to a high-energy diet in mice","volume":"24","author":"Czyzyk","year":"2010","journal-title":"FASEB J"},{"key":"10.1016\/j.jad.2022.01.004_bib0012","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1096\/fj.12-208041","article-title":"Mice lacking \u03b4-opioid receptors resist the development of diet-induced obesity","volume":"26","author":"Czyzyk","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.jad.2022.01.004_bib0013","first-page":"181","article-title":"The economic burden of chronic psychotic disorders in Ontario","volume":"19","author":"de Oliveira","year":"2016","journal-title":"J. Ment. Health Policy Econ."},{"key":"10.1016\/j.jad.2022.01.004_bib0014","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/YCO.0000000000000519","article-title":"Prospects for pharmacotherapies to treat alcohol use disorder: an update on recent human studies","volume":"32","author":"Farokhnia","year":"2019","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.jad.2022.01.004_bib0015","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"10.1016\/j.jad.2022.01.004_bib0016","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","article-title":"Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: systematic review and meta-analysis","volume":"191","author":"Hunt","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jad.2022.01.004_bib0017","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.schres.2021.04.009","article-title":"A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: results from the ENLIGHTEN-2 long-term extension","volume":"232","author":"Kahn","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2022.01.004_bib0018","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/wps.20060","article-title":"Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies","volume":"12","author":"Kane","year":"2013","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2022.01.004_bib0019","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/bmj.325.7358.243","article-title":"Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study","volume":"325","author":"Koro","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2022.01.004_bib0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S109285291900124X","article-title":"Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities","volume":"24","author":"Krogmann","year":"2019","journal-title":"CNS Spectr"},{"key":"10.1016\/j.jad.2022.01.004_bib0021","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/appi.ajp.2018.18030280","article-title":"Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia","volume":"176","author":"Martin","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2022.01.004_bib0022","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.4088\/JCP.7075cc4c","article-title":"Managing weight gain in patients with severe mental illness","volume":"70","author":"McIntyre","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2022.01.004_bib0023","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(20)31544-0","article-title":"Bipolar disorders","volume":"396","author":"McIntyre","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.jad.2022.01.004_bib0024","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/00325481.2019.1701823","article-title":"New discoveries for an old drug: a review of recent olanzapine research","volume":"132","author":"Meftah","year":"2020","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.jad.2022.01.004_bib0025","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2022.01.004_bib0026","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","article-title":"Lifetime prevalence of psychotic and bipolar i disorders in a general population","volume":"64","author":"Per\u00e4l\u00e4","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2022.01.004_bib0027","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2022.01.004_bib0028","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12769","article-title":"Efficacy and safety of a combination of olanzapine and samidorphan in adult patients with an acute exacerbation of schizophrenia: outcomes from the randomized, phase 3 enlighten-1 study","volume":"81","author":"Potkin","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2022.01.004_bib0029","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40263-013-0083-9","article-title":"Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective","volume":"27","author":"Rauch","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2022.01.004_bib0030","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis","volume":"73","author":"Samara","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2022.01.004_bib0031","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.clinthera.2018.09.002","article-title":"Pharmacokinetics and short-term safety of ALKS 3831, a fixed-dose combination of olanzapine and samidorphan, in adult subjects with schizophrenia","volume":"40","author":"Sun","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jad.2022.01.004_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.109881","article-title":"Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: results from a phase 1 QT\/QTc study","volume":"100","author":"Sun","year":"2020","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2022.01.004_bib0033","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.2337\/diabetes.54.12.3510","article-title":"Resistance to diet-induced obesity in \u03bc-opioid receptor\u2013deficient mice: evidence for a \u201cthrifty gene","volume":"54","author":"Tabarin","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.jad.2022.01.004_bib0034","unstructured":"U.S. Food and Drug Administration, Olanzapine and Samidorphan. Updated 5\/2021. Accessed 17\/08\/2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/213378s000lbl.pdf."},{"key":"10.1016\/j.jad.2022.01.004_bib0035","first-page":"1","article-title":"Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study","author":"Yagoda","year":"2020","journal-title":"CNS Spectr."}],"updated-by":[{"DOI":"10.1016\/j.jad.2022.02.010","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000}}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032722000039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032722000039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T14:49:39Z","timestamp":1673102979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032722000039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":35,"alternative-id":["S0165032722000039"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2022.01.004","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jad.2022.02.010","asserted-by":"object"}]},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olanzapine and samidorphan combination treatment: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2022.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}